Chapter 11  ·  Module 6

Lipid Management in Special Cardiovascular Populations

Visual summary — familial hypercholesterolemia, post-ACS, heart failure, diabetes, elderly, and chronic kidney disease

Familial Hypercholesterolemia — Heterozygous vs. Homozygous

Heterozygous FH (1 in 250)

Standard Escalation Works

  • Untreated LDL typically 190–400 mg/dL
  • Step 1: High-intensity statin (43–63% reduction)
  • Step 2: Add ezetimibe (+18–25%)
  • Step 3: Add PCSK9 inhibitor (+50–60%)
  • Triple combination achieves 70–85% total reduction
  • LDL receptor-dependent drugs are effective

Homozygous FH (1 in 300,000+)

LDL Receptor-Independent Agents Required

  • Untreated LDL typically 400–1,000 mg/dL
  • Two mutant LDL receptor alleles — minimal receptor function
  • Statins and ezetimibe: only 10–25% LDL reduction
  • PCSK9 inhibitors: largely ineffective without functional receptors
  • Lomitapide: blocks apoB-containing lipoprotein assembly (receptor-independent)
  • Evinacumab: blocks ANGPTL3; receptor-independent LDL lowering

Post-Acute Coronary Syndrome and Heart Failure

Post-acute coronary syndrome

Maximum Intensity Immediately

  • High-intensity statin within 24 hours regardless of LDL level
  • Early benefit from pleiotropic effects (plaque stabilization, anti-inflammatory)
  • LDL target: <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC)
  • Add ezetimibe at 4–8 weeks if not at target
  • Add PCSK9 inhibitor if still above target on dual therapy
  • Baseline LDL ≥100 mg/dL: consider early PCSK9 inhibitor

Heart failure — statin paradox

Statins Do Not Reduce HF Mortality

  • Two large randomized trials: no mortality benefit in chronic heart failure
  • Deaths in heart failure: pump failure and arrhythmia, not atherothrombotic events
  • Rule 1: Continue statin if patient has established ASCVD
  • Rule 2: Do NOT start statin solely for heart failure
  • Rule 3: Do not stop a well-tolerated statin in stable heart failure

Hypertriglyceridemia — Two Goals, Two Different Drugs

Moderate TG 135–499 mg/dL on statin

Goal: Cardiovascular Event Reduction

  • Patient: established ASCVD or diabetes with additional risk factors
  • Drug: icosapentaenoic acid ethyl ester 4 g/day
  • Class IIa recommendation (ACC/AHA)
  • Fibrates do NOT reduce cardiovascular events in this range

Severe TG ≥500 mg/dL

Goal: Pancreatitis Prevention

  • Acute pancreatitis risk becomes significant
  • Drug: fenofibrate (first-line)
  • Plus: very-low-fat diet, alcohol cessation, treat secondary causes
  • Add icosapentaenoic acid ethyl ester once TG falls below 500 mg/dL

Special Populations Quick Reference

Population Key Rule Preferred Agent(s) Critical Caution
Diabetes Statin foundation for all age 40–75; IPE for TG 135–499 on statin High-intensity statin; add IPE if TG elevated Non-HDL-C and apoB more relevant targets than LDL-C alone
Elderly — secondary prevention Continue high-intensity statin; no upper age cutoff High-intensity statin as tolerated Dose reduction for frailty; monitor for muscle symptoms
Elderly — primary prevention Individualize based on life expectancy and frailty Moderate-intensity statin preferred Deprescribing is evidence-supported in limited life expectancy
Chronic kidney disease (pre-dialysis) Statin therapy recommended; cardiovascular benefit established Atorvastatin (no dose adjustment needed) Cap rosuvastatin at 10 mg/day if eGFR <30; fenofibrate caution
Dialysis Do not initiate statin; continue if started before dialysis Continue existing statin if tolerated No cardiovascular mortality benefit demonstrated in dialysis
Renal transplant on cyclosporine High cardiovascular risk; treat aggressively Pravastatin or fluvastatin (lowest interaction) Avoid simvastatin and lovastatin; dose-reduce atorvastatin/rosuvastatin

Key Clinical Rules to Remember

Homozygous FH

Standard LDL receptor-dependent drugs (statins, ezetimibe, PCSK9 inhibitors) have markedly reduced efficacy. Lomitapide and evinacumab target LDL receptor-independent pathways and are required for meaningful LDL lowering in true receptor-negative patients.

Heart Failure Statin Paradox

Do not start statins solely for heart failure. Continue if the patient has atherosclerotic cardiovascular disease. Two large dedicated trials showed no mortality benefit from rosuvastatin in chronic heart failure despite robust LDL and CRP lowering.

Dialysis Paradox

Statins reduce cardiovascular events in pre-dialysis chronic kidney disease but not in dialysis patients. Do not initiate statin therapy in patients already on dialysis. This mirrors the heart failure paradox: the predominant cause of cardiovascular death changes in end-stage disease.